Amyloidosis - Dr Lachmann (London, UK)

1 Views

07/08/23

Dr. Helen Lachmann discusses prevalence, subtypes, diagnosis and treatment of amyloidosis in general, and of its major subcategories (AL-amyloidosis, AA-amyloidosis, ATTR (transthyretin)-amyloidosis). Dr. Lachmann is Professor of Medicine at the National Amyloidosis Centre at the University College London (UCL; Royal Free Campus) in London, UK. Dr. Lachmann has conducted seminal studies in the field of amyloidosis and published more than 200 papers on amyloidosis.

The interview was recorded on March 15th, 2022. Moderators: Priv.-Doz. Dr. Andreas Kronbichler (Cambridge, UK / Innsbruck, Austria), Priv.-Doz. Dr. Marlies Antlanger (Linz, Austria) and Prof. Dr. Gunnar Heine (Frankfurt / Homburg, Germany).

Articles discussed:

Natural history and outcome in systemic AA amyloidosis.
Lachmann HJ et al.
N Engl J Med. 2007 doi: 10.1056/NEJMoa070265.

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.
Beck DB et al.
N Engl J Med. 2020 doi: 10.1056/NEJMoa2026834.

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.
Edwards CV et al.
Blood. 2021 doi: 10.1182/blood.2020009039.

Systemic amyloidosis.
Wechalekar AD, Gillmore JD, Hawkins PN.
Lancet. 2016 doi: 10.1016/S0140-6736(15)01274-X.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Rajkumar SV et al.
Lancet Oncol. 2014 doi: 10.1016/S1470-2045(14)70442-5.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS et al.; ATTR-ACT Study Investigators.
N Engl J Med. 2018 doi: 10.1056/NEJMoa1805689.

AJKD Atlas of Renal Pathology: Hereditary and Other Non-AL Amyloidoses.
Fogo AB et al.
Am J Kidney Dis. 2015 doi: 10.1053/j.ajkd.2015.10.005.

Pathology and diagnosis of renal non-AL amyloidosis.
Sethi S, Theis JD.
J Nephrol. 2018 doi: 10.1007/s40620-017-0426-6.

AJKD Atlas of Renal Pathology: AL Amyloidosis.
Fogo AB, Lusco MA, Najafian B, Alpers CE.
Am J Kidney Dis. 2015 doi: 10.1053/j.ajkd.2015.10.006.

Transthyretin amyloidosis and the kidney.
Lobato L, Rocha A.
Clin J Am Soc Nephrol. 2012 doi: 10.2215/CJN.08720811

Molecular mechanisms of amyloidosis.
Merlini G, Bellotti V.
N Engl J Med. 2003 doi: 10.1056/NEJMra023144.

Clinical practice. Monoclonal gammopathy of undetermined significance.
Bladé J.
N Engl J Med. 2006 doi: 10.1056/NEJMcp052790.

Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis.
Sethi S et al.
Kidney Int. 2012 doi: 10.1038/ki.2012.108.

Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
Gertz MA, Dispenzieri A.
JAMA. 2020 doi: 10.1001/jama.2020.5493.